$MDGL
Madrigal Pharmaceuticals Inc

2013 Q4 Form 10-Q Financial Statement

#000110465913080239 Filed on November 04, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.500M $4.200M $3.400M
YoY Change 2.94% 50.0% 21.43%
% of Gross Profit
Research & Development $19.98M $17.62M $14.35M
YoY Change 39.23% 50.07% 32.16%
% of Gross Profit
Depreciation & Amortization $150.0K $100.0K $120.0K
YoY Change 25.0% -50.0% -58.62%
% of Gross Profit
Operating Expenses $23.44M $21.79M $17.70M
YoY Change 32.43% 49.9% 29.58%
Operating Profit -$23.44M -$21.79M -$17.70M
YoY Change 32.43% 49.9% 72.9%
Interest Expense -$718.0K -$721.0K -$420.0K
YoY Change 70.95% 57.77% -16.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$24.20M -$22.50M -$18.10M
YoY Change 33.7% 50.0% 69.16%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$24.20M -$22.50M -$18.10M
YoY Change 33.7% 50.0% 69.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$11.00M -$11.25M -$10.06M
COMMON SHARES
Basic Shares Outstanding 69.11M shares 69.06M shares 61.90M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.50M $53.40M $100.6M
YoY Change -9.05% -3.09% 153.4%
Cash & Equivalents $48.49M $25.48M $81.51M
Short-Term Investments $43.00M $27.90M $19.10M
Other Short-Term Assets $800.0K $1.400M $800.0K
YoY Change 0.0% 75.0% 33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $92.24M $54.74M $101.4M
YoY Change -9.02% -2.07% 151.66%
LONG-TERM ASSETS
Property, Plant & Equipment $1.553M $1.488M $1.174M
YoY Change 32.28% 23.49% -16.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.409M $433.0K $458.0K
YoY Change 207.64% -7.08% -27.42%
Total Long-Term Assets $2.962M $1.921M $1.632M
YoY Change 81.5% 12.14% -19.92%
TOTAL ASSETS
Total Short-Term Assets $92.24M $54.74M $101.4M
Total Long-Term Assets $2.962M $1.921M $1.632M
Total Assets $95.20M $56.66M $103.0M
YoY Change -7.59% -1.65% 143.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.589M $5.693M $5.661M
YoY Change 16.39% 54.28% 63.28%
Accrued Expenses $16.10M $12.80M $9.900M
YoY Change 62.63% 72.97% 33.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.500M $7.400M $7.900M
YoY Change 20.25% -6.33% 88.1%
Total Short-Term Liabilities $32.21M $25.93M $23.49M
YoY Change 37.13% 36.73% 55.04%
LONG-TERM LIABILITIES
Long-Term Debt $13.90M $16.10M $4.500M
YoY Change 208.89% 147.69% -63.71%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $13.91M $16.12M $4.465M
YoY Change 211.42% 149.61% -64.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.21M $25.93M $23.49M
Total Long-Term Liabilities $13.91M $16.12M $4.465M
Total Liabilities $46.11M $42.05M $27.95M
YoY Change 64.97% 65.41% 1.46%
SHAREHOLDERS EQUITY
Retained Earnings -$551.4M -$527.3M -$461.2M
YoY Change 19.56% 18.99% 15.76%
Common Stock $600.5M $541.9M $536.3M
YoY Change 11.97% 14.01% 29.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.09M $14.61M $75.07M
YoY Change
Total Liabilities & Shareholders Equity $95.20M $56.66M $103.0M
YoY Change -7.59% -1.65% 143.4%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q4
OPERATING ACTIVITIES
Net Income -$24.20M -$22.50M -$18.10M
YoY Change 33.7% 50.0% 69.16%
Depreciation, Depletion And Amortization $150.0K $100.0K $120.0K
YoY Change 25.0% -50.0% -58.62%
Cash From Operating Activities -$18.69M -$16.59M -$12.53M
YoY Change 49.16% 25.11% 19.45%
INVESTING ACTIVITIES
Capital Expenditures -$80.00K -$20.00K -$90.00K
YoY Change -11.11% -90.48% -76.32%
Acquisitions
YoY Change
Other Investing Activities -$15.06M $8.510M $6.600M
YoY Change -328.18% -228.36% -67.6%
Cash From Investing Activities -$15.15M $8.500M $6.520M
YoY Change -332.36% -224.27% -67.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 56.85M -210.0K 58.08M
YoY Change -2.12% -100.88% -83071.43%
NET CHANGE
Cash From Operating Activities -18.69M -16.59M -12.53M
Cash From Investing Activities -15.15M 8.500M 6.520M
Cash From Financing Activities 56.85M -210.0K 58.08M
Net Change In Cash 23.01M -8.300M 52.07M
YoY Change -55.81% -315.58% 452.17%
FREE CASH FLOW
Cash From Operating Activities -$18.69M -$16.59M -$12.53M
Capital Expenditures -$80.00K -$20.00K -$90.00K
Free Cash Flow -$18.61M -$16.57M -$12.44M
YoY Change 49.6% 26.97% 23.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, measurement of stock-based compensation, and the periods of performance under collaborative research and development agreements. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</font></p> <p style="TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt;">&#160;</p> </div>
us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2012Q3 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
us-gaap Revenue From Grants
RevenueFromGrants
147000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1174000 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1488000 USD
CY2013Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000 USD
CY2012Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
373000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
623000 USD
CY2013Q3 snta Accrued Liabilities Current Excluding Accrued Contract Research Costs
AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts
4497000 USD
CY2012Q4 snta Accrued Liabilities Current Excluding Accrued Contract Research Costs
AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts
5127000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">(1)&#160;Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Synta Pharmaceuticals Corp. (the Company) was incorporated in March&#160;2000 and commenced operations in July&#160;2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</font></p> <p style="TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> </div>
CY2013Q3 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
6000 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
21794000 USD
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
14539000 USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68930082 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69103073 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68930082 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69103073 shares
snta Total Revenues
TotalRevenues
147000 USD
CY2013Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17623000 USD
CY2012Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11743000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
51879000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
35061000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4171000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2796000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12236000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8324000 USD
us-gaap Operating Expenses
OperatingExpenses
64115000 USD
us-gaap Operating Expenses
OperatingExpenses
43385000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21794000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14539000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-64115000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-43238000 USD
CY2013Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-721000 USD
CY2012Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-457000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1915000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1429000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22515000 USD
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14996000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66030000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-44667000 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69047161 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60661720 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69024656 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58235263 shares
CY2013Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3000 USD
CY2012Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
5000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22518000 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14992000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66026000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44662000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4490000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2359000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
572000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
242000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-165000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25477000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81512000 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
54742000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
687000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
421000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9503000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-16463000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1082000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-25000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
32000 USD
snta Increase Decrease Accrued Contract And Research Costs
IncreaseDecreaseAccruedContractAndResearchCosts
3591000 USD
snta Increase Decrease Accrued Contract And Research Costs
IncreaseDecreaseAccruedContractAndResearchCosts
878000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-630000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-951000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-58721000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-41612000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
71183000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
45887000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
62367000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
29845000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
13500000 USD
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
2383000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
10000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12189000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-56035000 USD
us-gaap Interest Paid
InterestPaid
1335000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28960000 USD
snta Proceeds From Issuance Of Common Stock To Related Parties
ProceedsFromIssuanceOfCommonStockToRelatedParties
30759000 USD
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
2268000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
9000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
57442000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-633000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30075000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29442000 USD
CY2012Q4 snta Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains
CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains
3000 USD
CY2013Q3 snta Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains
CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains
6000 USD
CY2012Q4 snta Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Losses
CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses
1000 USD
dei Entity Registrant Name
EntityRegistrantName
SYNTA PHARMACEUTICALS CORP
dei Entity Central Index Key
EntityCentralIndexKey
0001157601
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1683000 USD
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
801000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2359000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4490000 USD
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
14284000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M29D
CY2013Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
233000 USD
CY2013Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
9451000 USD
CY2013Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
9214000 USD
CY2013Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4607000 USD
CY2013Q3 us-gaap Secured Debt
SecuredDebt
23505000 USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
69107506 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2013Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
27907000 USD
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
19087000 USD
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1358000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
786000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
101385000 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
433000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
458000 USD
CY2013Q3 us-gaap Assets
Assets
56663000 USD
CY2012Q4 us-gaap Assets
Assets
103017000 USD
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5693000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5661000 USD
CY2013Q3 snta Accrued Contract Research Costs
AccruedContractResearchCosts
8352000 USD
CY2012Q4 snta Accrued Contract Research Costs
AccruedContractResearchCosts
4761000 USD
CY2013Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
4000 USD
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
13000 USD
CY2013Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
7385000 USD
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
7924000 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
25931000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23486000 USD
CY2012Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1000 USD
CY2013Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
16120000 USD
CY2012Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
4464000 USD
CY2013Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
16120000 USD
CY2012Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4465000 USD
CY2013Q3 us-gaap Liabilities
Liabilities
42051000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
27951000 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
7000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
7000 USD
CY2013Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
541849000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
536277000 USD
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-527250000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-461220000 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
14612000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
75066000 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56663000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103017000 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001

Files In Submission

Name View Source Status
0001104659-13-080239-index-headers.html Edgar Link pending
0001104659-13-080239-index.html Edgar Link pending
0001104659-13-080239.txt Edgar Link pending
0001104659-13-080239-xbrl.zip Edgar Link pending
a13-19698_110q.htm Edgar Link pending
a13-19698_1ex31d1.htm Edgar Link pending
a13-19698_1ex31d2.htm Edgar Link pending
a13-19698_1ex32d1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g196981gai001.gif Edgar Link pending
g196981gai002.gif Edgar Link pending
g196981gai003.jpg Edgar Link pending
g196981gai004.jpg Edgar Link pending
g196981gai005.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snta-20130930.xml Edgar Link completed
snta-20130930.xsd Edgar Link pending
snta-20130930_cal.xml Edgar Link unprocessable
snta-20130930_def.xml Edgar Link unprocessable
snta-20130930_lab.xml Edgar Link unprocessable
snta-20130930_pre.xml Edgar Link unprocessable